Miami-based eMed, a digital health company that manages GLP-1 weight-loss programs for employers, just announced it has raised $200 million in Series A funding at a valuation of over $2 billion.
The round brings together lead investor AON Consulting and NFL legend Tom Brady, who was also named eMed’s Chief Wellness Officer. eMed CEO Linda Yaccarino, who was named to eMed’s top post last August, participated in the round, too. Paragon Biosciences CEO Jeff Aronin, Joe Lonsdale of 8VC and a Palantir co-founder, and Chicago Cubs Chairman Tom Ricketts, among others, also invested.
“I believe eMed’s empathic agentic AI platform, combined with the strength of its people and partners, represents a true winning formula. That conviction is why I’ve chosen to invest both my time as Founding Chief Wellness Officer and my capital in the company,” said Brady, in a statement.
eMed was founded in 2020, and at first sold at-home Covid-19 tests and other medications before pivoting to weight loss. Today, eMed provides GLP-1 medications and chronic weight management care programs related to obesity and type 2 diabetes. The company partners with employers and government payers to manage clinically supervised GLP-1 usage, a class of obesity and diabetes drugs whose cost has limited broader insurance coverage.
Indeed, GLP-1 medications are the most requested workplace benefit, yet only one in five companies provide the benefit. eMed says it has achieved more than 90% member adherence, more than double the industry norm, and employees are seeing average weight loss of 21 pounds, the company reports.
eMed is on a mission to be the go-to employer platform for population health at scale. To that end, proceeds from the new financing will be used to further advance eMed’s agentic AI platform, which helps deliver continuous, personalized care. The funding round will also support and finance a new healthcare payment model designed to help employers bend the healthcare cost curve, the company said in its press release.
“The raise confirms eMed momentum and establishes us as the definitive company for population health and helping employers break the runaway health care costs and break their cost curve,” Yaccarino said in an interview on FOX Business Network’s Mornings With Maria.
As for what’s next, Yaccarino told Axios that eMed plans to “look across the peptide ecosystem” or additional therapies and that the new capital should help it “expand globally.”
READ MORE IN REFRESH MIAMI:
- OpenEvidence lands $250M to further develop the AI doctors already rely on
- ILiAD Biotechnologies of Weston raises $115M to advance whooping cough vaccine
- Biobeat raises a $50M Series B for its US expansion
- Former X CEO Linda Yaccarino is now at the helm of eMed
- 8+ things to know in #MiamiTech: News from BRiC, Related Ross, WeWork, GBI, Brightline, The Source & more - September 14, 2026
- a16z plants American Dynamism base in West Palm Beach - September 10, 2026
- DermaSensor raises$5M and opens community round on Wefunder amid commercial growth - September 9, 2026